Artera
Artera is a leading precision medicine company developing AI tests to personalize cancer therapy. Their mission is to enable personalized cancer treatment and shared decision-making between clinicians and patients, leveraging advanced AI technology to improve treatment accuracy and outcomes.
Industries
Nr. of Employees
medium (51-250)
Artera
6800 Southpoint Pkwy Suite 950, Jacksonville, Florida 32216
Products
AI-enabled multimodal biomarker test for localized prostate cancer (prostate biopsy assay)
A multimodal AI assay that evaluates digitized biopsy images and clinical variables to produce individualized predictive and prognostic results to support treatment decisions for localized prostate cancer; provided as a laboratory-developed test.
AI-enabled multimodal biomarker test for localized prostate cancer (prostate biopsy assay)
A multimodal AI assay that evaluates digitized biopsy images and clinical variables to produce individualized predictive and prognostic results to support treatment decisions for localized prostate cancer; provided as a laboratory-developed test.
Services
Provision of a clinically available laboratory-developed diagnostic test that analyzes digitized biopsy slides and clinical data to generate predictive and prognostic reports for localized prostate cancer. Testing performed in a CLIA-certified laboratory; ordering limited to clinicians.
Registry trial design and execution to collect real-world outcomes and measure clinical impact of the diagnostic test in practice.
Provision of a clinically available laboratory-developed diagnostic test that analyzes digitized biopsy slides and clinical data to generate predictive and prognostic reports for localized prostate cancer. Testing performed in a CLIA-certified laboratory; ordering limited to clinicians.
Registry trial design and execution to collect real-world outcomes and measure clinical impact of the diagnostic test in practice.
Expertise Areas
- AI-driven biomarker development
- Digital histopathology and image analytics
- Clinical validation and use of Phase 3 trial datasets
- Clinical laboratory testing (CLIA LDT workflows)
Key Technologies
- Multimodal deep learning
- Digital slide scanning and image preprocessing
- Cloud-based analytics (region-aware deployments)
- AES-256 encryption
News & Updates
Chicago, IL. Embrace new connections with colleagues from around the world, immerse yourself in cutting-edge scientific discoveries, and add your voice to conversations that will transform tomorrow’s outcomes.
ArteraAI has received Medicare reimbursement approval for its prostate cancer test, supporting broader access and affordability.
Artera’s MMAI platform has been recognized among TIME’s 2024 Best Inventions for its innovative approach to cancer prognosis and therapy personalization.
Recognition of Artera’s MMAI platform among TIME’s 2024 Best Inventions for its innovation in cancer prognosis and personalized therapy.
Chicago, IL. Embrace new connections with colleagues from around the world, immerse yourself in cutting-edge scientific discoveries, and add your voice to conversations that will transform tomorrow’s outcomes.
ArteraAI has received Medicare reimbursement approval for its prostate cancer test, supporting broader access and affordability.
Artera’s MMAI platform has been recognized among TIME’s 2024 Best Inventions for its innovative approach to cancer prognosis and therapy personalization.
Recognition of Artera’s MMAI platform among TIME’s 2024 Best Inventions for its innovation in cancer prognosis and personalized therapy.